Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind Placebo-Controlled Randomised Phase 1b Study of the Pharmacokinetics of ALE.F02 in Patients With Advanced Liver Fibrosis and/or With Mild Cirrhosis

NCT05939947 is registered in ClinicalTrials.gov with Alentis Therapeutics AG as lead sponsor.

NCT NCT05939947
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05939947 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind Placebo-Controlled Randomised Phase 1b Study of the Pharmacokinetics of ALE.F02 in Patients With Advanced Liver Fibrosis and/or With Mild Cirrhosis
Lead sponsor
Alentis Therapeutics AG
Phase
Phase 1
Overall status
Completed
Start date
April 1, 2023
Completion date
October 30, 2024
Enrollment
41 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

advanced liver fibrosis, liver cirrhosis